10 results about "Myeloblastic leukemia" patented technology

A human chronic myeloid leukemia cell line and the use thereof. The human chronic myeloid leukemia cell line is the first cell line internationally established from chronic-phase leukemia cells of chronic myeloid leukemia, and was named human chronic myeloid leukemia cell YYXY-M6, which was deposited at the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on July 24, 2023, under the deposit number of CCTCC NO: C2023219. The leukemia cell line exhibits primitive cell morphology and has three karyotypes, i.e. t(6:11)(q25:q23), del(11)(q23) and normal karyotype (46, XX); is BCR-ABL gene-negative; has good in-vitro proliferation ability; can be used as cellular material for the study of the mechanism of occurrence and development of the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and of BCR-ABL gene-negative chronic myeloid leukemia, and for the in-vitro study of individualized treatment; and can also be used for both in-vitro and in-vivo studies of drug screening and evaluation for the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and BCR-ABL gene-negative chronic myeloid leukemia, providing guidance for clinical medication.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38′ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and / or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

The invention discloses an application of a disulfide bond isomerase single-domain antibody in preparation of a product for treating and / or preventing leukemia, the disulfide bond isomerase single-domain antibody comprises a variable region, and the variable region comprises CDR1, CDR2 and CDR3; the amino acid sequences of CDR1-CDR3 of the disulfide bond isomerase single-domain antibody are sequentially as shown in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, and the CDR1-CDR3 are defined according to an IMGT definition scheme. The single-domain antibody provided by the invention can be used for remarkably inhibiting the growth of subcutaneous transplanted tumors of Ba / F3BCR-ABLT315I cells in nude mice, and has an obvious inhibiting effect on drug-resistant chronic granulocytic leukemia.

Methods of predicting whether a subject with chronic myelogenous leukaemia (CML) is at risk of relapse following cessation of a treatment for CML, whether a subject with CML will achieve TFR following cessation of a treatment for CML, and selecting a subject for treatment, wherein the subject has CML or has been diagnosed with CML are disclosed herein. The methods comprise determining the expression of one or more genes regulated by PRC1. Also provided are kits and antigen-binding molecules suitable for use in the disclosed methods.

The invention relates to the treatment of chronic myeloid leukemia (CML). In particular it relates to the treatment of CML with inhibitors of mitochondrial pyruvate transport, which are able to target leukemic stem cells (LSCs) which are resistant to therapy with tyrosine kinase inhibitors (TKIs). Combination therapies with BCR-ABL kinase inhibitors are also described.

The present invention discloses a drug combination and application for treating chronic myeloid leukemia, belonging to the field of medical technology. The present invention uses chronic myeloid leukemia cells KBM5, KU-812, and primary cells from clinical patients as research subjects. Disulfiram and TKIs are administered alone or in combination through in vitro drug addition experiments, and cell viability and cell proliferation are measured. The results show that DSF or TKIs alone have certain anti-tumor effects, and the combination of disulfiram and TKIs can significantly enhance the anti-tumor effect of TKIs. Based on this, we speculate that the combination of disulfiram and TKIs can be applied to the clinical treatment of chronic myeloid leukemia.

The invention discloses a targeted protein degradation agent utilizing an autophagy-lysosome pathway as well as a preparation method and application of the targeted protein degradation agent, and belongs to the technical field of degradation agent preparation. The preparation method comprises the following steps: carrying out nucleophilic substitution reaction on a GW5074 derivative and a linker arm precursor to obtain a GW5074 derivative-linker arm intermediate, and coupling the GW5074 derivative-linker arm intermediate with demethylated imatinib to obtain the targeted protein degradation agent utilizing the autophagy-lysosome pathway. The protein degradation agent disclosed by the invention is relatively few in preparation steps, easy to synthesize and relatively high in yield, and can be used for preparing medicines for treating cancers, particularly antitumor medicines for treating chronic granulocytic leukemia.

The invention belongs to the technical field of medicines, and provides application of sterone compounds in uniflower swisscentaury roots in preparation of medicines for inhibiting protein tyrosine phosphatase. Experimental research finds that the sterone compounds shown in the formula I and the formula II have inhibitory activity on T-cell protein tyrosine phosphatase (TCPTP) and protein tyrosine phosphatase 1B (PTP1B), and can be used for preparing drugs for inhibiting TCPTP and / or PTP1B and drugs for preventing, delaying or treating type II diabetes mellitus and / or obesity; the sterone compounds with the structural formulas as shown in the formula II and the formula III have inhibitory activity on non-receptor protein tyrosine phosphatase 9 (MEG2), can be used for preparing a medicine for inhibiting MEG2, preparing a medicine for preventing, delaying or treating chronic granulocytic leukemia, and also can be used for preparing a medicine for preventing, delaying or treating type II diabetes mellitus and / or obesity. The new application lays a foundation for deep research of active ingredients of uniflower swisscentaury roots and development of new drugs.

The present invention provides an H3S28 phosphorylation inhibitor or a composition containing the same. [Solution] A histone H3 phosphorylation inhibitor comprising a benzaldehyde compound or a pharmaceutically acceptable salt thereof is provided. The inhibitor or a composition comprising the same can be used to prevent, treat, or treat various cancers involving the H3S28ph protein (e.g., hepatic cancer, pancreatic cancer, lung cancer, ovarian cancer, colon adenocarcinoma, chronic myeloid leukemia, pancreatic ductal adenocarcinoma, malignant kidney tumor, breast cancer, melanoma, etc.), radiation-resistant cancers of these cancers, heart failure, and their complications, or to treat poor prognoses, by inhibiting the expression of the H3S28ph protein. Preferably, the benzaldehyde compound is benzaldehyde, 5,6-O-benzylidene-L-ascorbic acid, monosodium 5,6-O-benzylidene-L-ascorbic acid, 4,6-O-benzylidene-D-glucopyranose, or N-benzylideneethylamine.

To provide a composition applicable for prevention, treatment, or treatment of poor prognosis of various cancers involving LIN28B protein activity (e.g. hepatocellular carcinoma, pancreatic cancer, lung cancer, ovarian cancer, colon adenocarcinoma, chronic myelogenous leukemia, pancreatic ductal adenocarcinoma, malignant kidney tumor, breast cancer, and melanoma).SOLUTION: A benzaldehyde compound that inhibits expression of LIN28B protein is provided. The LIN28B inhibitor of the present invention is also useful for diabetes, pneumonia, hepatic cirrhosis, renal disorders, nephrosclerosis, and cardiotoxicity, and effectively serves as a component in nutritional compositions, supplements, foods, and beverages.SELECTED DRAWING: None